Adragos is growing rapidly, with three locations in Europe and five globally. To further its product development service offering, it has acquired the capability to provide end-to-end integrated pharmaceutical product development services. Additionally, Adragos has agreed to work on further product development activities for Clinigen.
Adragos Pharma GmbH, a pharmaceutical contract development organization (CDMO) based in Munich, has cogently wrapped up the acquisition of Lamda Laboratories S.A. in Athens. A result of this transaction is that Adragos Pharma now operates three sites within Europe and five worldwide.
Adragos has enhanced its pharmaceutical product development, regulatory affairs, and supply chain management services for globally-based clients by acquiring Lamda Laboratories. This significant increase in offerings grants them additional capabilities.
Clinigen’s trust in the reliability of Lamda, its only development center, has made it a go-to option as a contract development organization (CDO) for external customers. In the future, Clinigen will continue to draw upon this dependable service for its purposes.
Located a 15-minute drive from the Athens airport, the Athens site has demonstrated successful results due to its reliable quality systems and advanced technology. Its capabilities make it suitable for complex, highly potent pharmaceutical projects delivered on time.
Today at the facility, in front of the workforce, the official handover of Adragos Pharma was conducted. CEO Dr. Andreas Raabe expressed his delight in ensuring a successful transaction. The staff stayed on-site, and no changes were made to their roles or responsibilities.
Lamda is pivotal to our organization, for it aids us in broadening our value chain coverage beyond simply manufacturing and into Development. This allows us to target a new demographic of consumers.
We are pleased to offer Lamda customers production capacity within our Adragos Group and a broader service offering for existing Adragos Manufacturing customers. This allows both groups of customers to benefit from expanded services and capacity.
Truist Securities acted as the buy-side advisor to Adragos Pharma GmbH in the transaction, though the exact terms of it will remain undisclosed.
Adragos Pharma, headquartered in Munich, Germany, and renowned for its top-notch customer service and data centricity, strives to become a global leader in the CDMO sector. To that end, the company plans to expand its production network with acquisitions in North America, Europe, and Japan.
Adragos Pharma, operating four production sites in France, Germany, and Japan, pursues a buy-and-build growth strategy backed by two renowned organizations: FSN Capital, a Northern European private equity firm, and Prange Group, a German family office.
Clinigen is a leading provider of ethical access to medicines, with its main goal being the delivery of the appropriate medication for every patient at the opportune moment. The company is a renowned global specialist in pharmaceutical services.
Clinigen, with more than 1,200 employees in 15 countries and providing access to over 120 countries each year, provides comprehensive services along the medical product lifecycle – from clinical study to commercialization – to multiple pharmaceutical and biotech companies situated across the continents of North America, Europe, Africa, and Asia Pacific.